Circulating ACE2 in cardiovascular and kidney diseases

Current Medicinal Chemistry

Volumn 24, Issue 30, 2017, Pages 3231-3241

  Anguiano, L ^a,b   Riera, M ^a   Pascual, J ^a   Soler, M J ^a  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Angiotensin converting enzyme 2; Biomarker; Cardiovascular disease; Chronic kidney disease; Diabetes; Reninangiotensin system

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE;

AGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY DISEASE; MOLECULAR PATHOLOGY; NONHUMAN; PROTEIN DOMAIN; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEX DIFFERENCE; ANIMAL; BLOOD;

ANIMALS; BIOMARKERS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY DISEASES; PEPTIDYL-DIPEPTIDASE A;

EID: 85040069579     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867324666170414162841     Document Type: Review

References (83)

1. Gregg, E.W.; Cheng, Y.J.; Saydah, S.; Cowie, C.; Garfield, S.; Geiss, L.; Barker, L. Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: Findings from the national health interview survey. Diabetes Care, 2012, 35, 1252-1257.
2. Guariguata, L.; Whiting, D.R.; Hambleton, I.; Beagley, J.; Linnenkamp, U.; Shaw, J.E. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res. Clin. Pract., 2014, 103, 137-149.
3. Hsu, R.K.; Powe, N.R. Recent trends in the prevalence of chronic kidney disease. Curr. Opin. Nephrol. Hypertens., 2017, doi:10.1097/MNH.0000000000000315.
4. Herzog, C.A. Asinger, R.W.; Berger, A.K.; Charytan, D.M.; Diez, J.; Hart, R.G.; Eckardt, K.U.; Kasiske, B.L.; McCullough, P.A.; Passman, R.S.; DeLoach, S.S.; Pun, P.H.; Ritz, E. Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: Improving global outcomes (KDIGO). Kidney Int., 2011, 80, 572-586.
5. Chen, J.; Budoff, M.J.; Reilly, M.P.; Yang, W.; Rosas, S.E.; Rahman, M.; Zhang, X.; Roy, J.A.; Lustigova, E.; Nessel, L.; Ford, V.; Raj, D.; Porter, A.C.; Soliman, E.Z.; Wright, J.T. Jr.; Wolf, M.; He, J.; CRIC Investigators. Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease. JAMA Cardiol., 2017, 2, 635-643.
6. Keith, D.S.; Nichols, G.A.; Gullion, C.M.; Brown, J.B.; Smith, D.H. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch. Intern. Med., 2004, 164, 659-663.
7. Go, A.S.; Chertow, G.M.; Fan, D.; McCulloch, C.E.; Hsu, C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med., 2004, 351, 1296-1305.
8. Chang, A.; Kramer, H. Should eGFR and albuminuria be added to the framingham risk score? Chronic kidney disease and cardiovascular disease risk prediction. Nephron Clin. Pract., 2011, 119, 171-178.
9. Coll, B.; Betriu, A.; Martinez-Alonso, M.; Borras, M.; Craver, L.; Amoedo, M.L.; Marco, M.P.; Sarro, F.; Junyent, M.; Valdivielso, J.M.; Fernandez, E. Cardiovascular risk factors underestimate atherosclerotic burden in chronic kidney disease: Usefulness of non-invasive tests in cardiovascular assessment. Nephrol. Dial. Transplant., 2010, 25, 3017-3025.
10. Navar, L.G. Intrarenal renin-angiotensin system in regulation of glomerular function. Curr. Opin. Nephrol. Hypertens., 2014, 23, 38-45.
11. Dzau, V. The cardiovascular continuum and reninangiotensin-aldosterone system blockade. J. Hypertens. Suppl., 2005, 23, S9-S17.
12. Kobori, H.; Nangaku, M.; Navar, L.G.; Nishiyama, A. The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev., 2007, 59, 251-287.
13. Ferrario, C.M. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J. Renin. Angiotensin. Aldosterone. Syst., 2006, 7, 3-14.
14. Brewster, U.C.; Perazella, M.A. The renin-angiotensinaldosterone system and the kidney: Effects on kidney disease. Am. J. Med., 2004, 116, 263-272.
15. Donoghue, M.; Hsieh, F.; Baronas, E.; Godbout, K.; Gosselin, M.; Stagliano, N.; Donovan, M.; Woolf, B.; Robison, K.; Jeyaseelan, R.; Breitbart, R.E.; Acton, S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res., 2000, 87, E1-E9.
16. Tipnis, S.R.; Hooper, N.M.; Hyde, R.; Karran, E.; Christie, G.; Turner, A.J. A human homolog of angiotensinconverting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem., 2000, 275, 33238-33243.
17. Vickers, C.; Hales, P.; Kaushik, V.; Dick, L.; Gavin, J.; Tang, J.; Godbout, K.; Parsons, T.; Baronas, E.; Hsieh, F.; Acton, S.; Patane, M.; Nichols, A.; Tummino, P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem., 2002, 277, 14838-14843.
18. Bindom, S.M.; Lazartigues, E. The sweeter side of ACE2: Physiological evidence for a role in diabetes. Mol. Cell. Endocrinol., 2009, 302, 193-202.
19. Santos, R.A.S.; Ferreira, A.J.; Simoes E Silva, A.C. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp. Physiol., 2008, 93, 519-527.
20. Hamming, I.; Timens, W.; Bulthuis, M.L.; Lely, A.T.; Navis, G.; van Goor, H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol., 2004, 203, 631-637.
21. Herath, C.B.; Warner, F.J.; Lubel, J.S.; Dean, R.G.; Jia, Z.; Lew, R.A.; Smith, A.I.; Burrell, L.M.; Angus, P.W. Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J. Hepatol., 2007, 47, 387-395.
22. Xu, P.; Sriramula, S.; Lazartigues, E. ACE2/ANG-(1-7)/Mas pathway in the brain: The axis of good. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2011, 300, R804-R817.
23. Riviere, G.; Michaud, A.; Breton, C.; VanCamp, G.; Laborie, C.; Enache, M.; Lesage, J.; Deloof, S.; Corvol, P.; Vieau, D. Angiotensin-converting enzyme 2 (ACE2) and ACE activities display tissue-specific sensitivity to undernutrition-programmed hypertension in the adult rat. Hypertension 2005, 46, 1169-1174.
24. Gembardt, F.; Sterner-Kock, A.; Imboden, H.; Spalteholz, M.; Reibitz, F.; Schultheiss, H.P.; Siems, W.E.; Walther, T. Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides, 2005, 26, 1270-1277.
25. Crackower, M.A.; Sarao, R.; Oudit, G.Y.; Yagil, C.; Kozieradzki, I.; Scanga, S.E.; Oliveira-dos-Santos, A.J.; da Costa, J.; Zhang, L.; Pei, Y.; Scholey, J.; Ferrario, C.M.; Manoukian, A.S.; Chappell, M.C.; Backx, P.H.; Yagil, Y.; Penninger, J.M. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature, 2002, 417, 822-828.
26. Santos, R.A.; Simoes e Silva, A.C.; Maric, C.; Silva, D.M.; Machado, R.P.; de Buhr, I.; Heringer-Walther, S.; Pinheiro, S.V.; Lopes, M.T.; Bader, M.; Mendes, E.P.; Lemos, V.S.; Campagnole-Santos, M.J.; Schultheiss, H.P.; Speth, R.; Walther, T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. USA, 2003, 100, 8258-8263.
27. Oudit, G.Y.; Herzenberg, A.M.; Kassiri, Z.; Wong, D.; Reich, H.; Khokha, R.; Crackower, M.A.; Backx, P.H.; Penninger, J.M.; Scholey, J.W. Loss of angiotensinconverting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am. J. Pathol., 2006, 168, 1808-1820.
28. Clotet, S.; Soler, M.J.; Rebull, M.; Gimeno, J.; Gurley, S.B.; Pascual, J.; Riera, M. Gonadectomy prevents the increase in blood pressure and glomerular injury in angiotensin-converting enzyme 2 knockout diabetic male mice. Effects on renin-angiotensin system. J. Hypertens., 2016, 34, 1752-1765.
29. Oudit, G.Y.; Liu, G.C.; Zhong, J.; Basu, R.; Chow, F.L.; Zhou, J.; Loibner, H.; Janzek, E.; Schuster, M.; Penninger, J.M.; Herzenberg, A.M.; Kassiri, Z.; Scholey, J.W. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes, 2010, 59, 529-538.
30. Black, R.A.; Rauch, C.T.; Kozlosky, C.J.; Peschon, J.J.; Slack, J.L.; Wolfson, M.F.; Castner, B.J.; Stocking, K.L.; Reddy, P.; Srinivasan, S.; Nelson, N.; Boiani, N.; Schooley, K.A.; Gerhart, M.; Davis, R.; Fitzner, J.N.; Johnson, R.S.; Paxton, R.J.; March, C.J.; Cerretti, D.P. A metalloproteinase disintegrin that releases tumour-necrosis factoralpha from cells. Nature, 1997, 385, 729-733.
31. Beldent, V.; Michaud, A.; Wei, L.; Chauvet, M.T.; Corvol, P. Proteolytic release of human angiotensin-converting enzyme. Localization of the cleavage site. J. Biol. Chem., 1993, 268, 26428-26434.
32. Palecanda, A.; Walcheck, B.; Bishop, D.K.; Jutila, M.A. Rapid activation-independent shedding of leukocyte Lselectin induced by cross-linking of the surface antigen. Eur. J. Immunol.,1992, 22, 1279-1286.
33. Moss, M.L.; Jin, S.L.; Milla, M.E.; Bickett, D.M.; Burkhart, W.; Carter, H.L.; Chen, W.J.; Clay, W.C.; Didsbury, J.R.; Hassler, D.; Hoffman, C.R.; Kost, T.A.; Lambert, M.H.; Leesnitzer, M.A.; McCauley, P.; McGeehan, G.; Mitchell, J.; Moyer, M.; Pahel, G.; Rocque, W.; Overton, L.K.; Schoenen, F.; Seaton, T.; Su, J.L.; Becherer, J.D. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature, 1997, 385, 733-736.
34. Lambert, D.W.; Yarski, M.; Warner, F.J.; Thornhill, P.; Parkin, E.T.; Smith, A.I.; Hooper, N.M.; Turner, A.J. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J. Biol. Chem., 2005, 280, 30113-30119.
35. Chodavarapu, H.; Grobe, N.; Somineni, H.K.; Salem, E.S.; Madhu, M.; Elased, K.M. Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion. PLoS One, 2013, 8, e62833.
36. Salem, E.S.B.; Grobe, N.; Elased, K.M. Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice. Am. J. Physiol. Renal Physiol., 2014, 306, F629-F369.
37. Somineni, H.K.; Boivin, G.P.; Elased, K.M. Daily exercise training protects against albuminuria and angiotensin converting enzyme 2 shedding in db/db diabetic mice. J. Endocrinol., 2014, 221, 235-251.
38. Xiao, F.; Zimpelmann, J.; Agaybi, S.; Gurley, S.B.; Puente, L.; Burns, K.D. Characterization of angiotensin-converting enzyme 2 ectodomain shedding from mouse proximal tubular cells. PLoS One, 2014, 9, e85958.
39. Riera, M.; Marquez, E.; Clotet, S.; Gimeno, J.; Roca-Ho, H.; Lloreta, J.; Juanpere, N.; Batlle, D.; Pascual, J.; Soler, M.J. Effect of insulin on ACE2 activity and kidney function in the non-obese diabetic mouse. PLoS One, 2014, 9, e84683.
40. Wysocki, J.; Ye, M.; Soler, M.J.; Gurley, S.B.; Xiao, H.D.; Bernstein, K.E.; Coffman, T.M.; Chen, S.; Batlle, D. ACE and ACE2 activity in diabetic mice. Diabetes, 2006, 55, 2132-2139.
41. Burrell, L.M.; Burchill, L.; Dean, R.G.; Griggs, K.; Patel, S.K.; Velkoska, E. Chronic kidney disease: Cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition. Exp. Physiol., 2012, 97, 477-485.
42. Rice, G.I.; Jones, A.L.; Grant, P.J.; Carter, A.M.; Turner, A.J.; Hooper, N.M. Circulating activities of angiotensinconverting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension, 2006, 48, 914-920.
43. Lew, R.A.; Warner, F.J.; Hanchapola, I.; Yarski, M.A.; Ramchand, J.; Burrell, L.M.; Smith, A.I. Angiotensinconverting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp. Physiol., 2008, 93, 685-693.
44. Ortiz-Perez, J.T.; Riera, M.; Bosch, X.; De Caralt, T.M.; Perea, R.J.; Pascual, J.; Soler, M.J. Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: A prospective controlled study. PLoS One, 2013, 8, e61695.
45. Soler, M.J.; Riera, M.; Crespo, M.; Mir, M.; Marquez, E.; Pascual, M.J.; Puig, J.M.; Pascual, J. Circulating angiotensin-converting enzyme 2 activity in kidney transplantation: a longitudinal pilot study. Nephron. Clin. Pract., 2012, 121, c144-c150.
46. Soro-Paavonen, A.; Gordin, D.; Forsblom, C.; Rosengard-Barlund, M.; Waden, J.; Thorn, L.; Sandholm, N.; Thomas, M.C.; Groop, P.H.; FinnDiane Study Group. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J. Hypertens., 2012, 30, 375-383.
47. Uri, K.; Fagyas, M.; Kertesz, A.; Borbely, A.; Jenei, C.; Bene, O.; Csanadi, Z.; Paulus, W.J.; Edes, I.; Papp, Z.; Toth, A.; Lizanecz, E. Circulating ACE2 activity correlates with cardiovascular disease development. J. Renin-Angiotensin-Aldosterone Syst., 2016, 17, pii, 1470320316-668435.
48. Anguiano, L.; Maria, V.; Moli, T.; Soria, M.; Regidor, A.; Jose, M.; Jaume, A.; Esther, P.; Coloma, A.; Rubio, B.; Rodriguez, B.; Sara, B.G.; Jordi, B.S.; Josep, B.A.; Romero, C.; Juan, B.; Salome, M.C.; Jesus, C.V.; Pilar, C.A.; Jordi, C.B.; Aleix, C.A.; Elisabet, M.J.; Jesus, C.P.; Secundino, C.G.; Saray, L.P.; Lourdes, C.M.; Isabel, C.M.; Teresa, C.J.; Marta, C.I.; Fernando de, A.; Covadonga, H.O.; Gabriel, de Ade L.M.; Dolores del, P.Y.; Rafael, D.T.; Marta, D.; Veronica, D.; Sara, E.T.M.; Jose, F.R.M.; Loreto, F.R.; Guillermina, F.; Antonio, G.S.; Cesar, G.C.; Herrera, G.; Antonio, L.; Mercedes, G.M.; Luis, G.S.; Maria, A.; Luis, G.J.; Emma, H.L.; Luis, L.J.; Antonio, L.C.; Alvarez, M.; Pedro, J.; Nadia, M.A.; Jesus, M.G.; Alberto, M.C.; Maria, M.V.; Isabel, M.; Inigo, M.E.; Silvia, M.L.; Ricardo, M.M.; Antonia, M.V.; Ana, Beatriz, M.D.; Gonzalez, N.; Juan, F.; Javier, N.; Agustin, C.; Enrique, N.F.; Alberto, O.; Beatriz, F.; Vicente, P.; Miguel, P.F.; Ana P.D.; Celestino, P.H.M.; Dolores, P.G.; Mario, P.V.; Carmina, P.M.; Maite, R.G.; Esther, R.; Pilar, R.; Mercedes, S.L.; Puerto, M.; Isabel, A.; Tomero, S.; Antonio, J.; Emilio, S.J.; Ramon, S.L.; Ramon, S.; Maria, S.; Oreto, P.; Fernando, S.; Daniel, T.; Fernando, T.M.; Carrasco, U.; Javier, J.; Ildefonso, V.C.M.; Merce, Vdel.P.; Ruiz, V.; Rafael, C. Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease. Nephrol. Dial. Transplant., 2015, 30, 1176-1185.
49. Burchill, L.; Velkoska, E.; Dean, R.G.; Lew, R.A.; Smith, A.I.; Levidiotis, V.; Burrell, L.M. Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression. Exp. Physiol., 2008, 93, 622-630.
50. Marre, M.; Bernadet, P.; Gallois, Y.; Savagner, F.; Guyene, T.T.; Hallab, M.; Cambien, F.; Passa, P.; Alhenc-Gelas, F. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes,1994, 43, 384-388.
51. Burrell, L.M.; Risvanis, J.; Kubota, E.; Dean, R.G.; MacDonald, P.S.; Lu, S.; Tikellis, C.; Grant, S.L.; Lew, R.A.; Smith, A.I.; Cooper, M.E.; Johnston, C.I. Myocardial infarction increases ACE2 expression in rat and humans. Eur. Heart J., 2005, 26, 369-375.
52. Zulli, A.; Burrell, L.M.; Widdop, R.E.; Black, M.J.; Buxton, B.F.; Hare, D.L. Immunolocalization of ACE2 and AT2 receptors in rabbit atherosclerotic plaques. J. Histochem. Cytochem., 2006, 54, 147-150.
53. Sluimer, J.C.; Gasc, J.M.; Hamming, I.; van Goor, H.; Michaud, A.; van den Akker, L.H.; Jutten, B.; Cleutjens, J.; Bijnens, A.P.; Corvol, P.; Daemen, M.J.; Heeneman, S. Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. J. Pathol., 2008, 215, 273-279.
54. Zisman, L.S.; Keller, R.S.; Weaver, B.; Lin, Q.; Speth, R.; Bristow, M.R.; Canver, C.C. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: Evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation, 2003, 108, 1707-1712.
55. Goulter, A.B.; Goddard, M.J.; Allen, J.C.; Clark, K.L. ACE2 gene expression is up-regulated in the human failing heart. BMC Med., 2004, 2, 19.
56. Oudit, G.Y.; Kassiri, Z.; Patel, M.P.; Chappell, M.; Butany, J.; Backx, P.H.; Tsushima, R.G.; Scholey, J.W.; Khokha, R.; Penninger, J.M. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc. Res., 2007, 75, 29-39.
57. Huentelman, M.J.; Grobe, J.L.; Vazquez, J.; Stewart, J.M.; Mecca, A.P.; Katovich, M.J.; Ferrario, C.M.; Raizada, M.K. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp. Physiol., 2005, 90, 783-790.
58. Zhang, C.; Zhao, Y.X.; Zhang, Y.H.; Zhu, L.; Deng, B.P.; Zhou, Z.L.; Li, S.Y.; Lu, X.T.; Song, L.L.; Lei, X.M.; Tang, W.B.; Wang, N.; Pan, C.M.; Song, H.D.; Liu, C.X.; Dong, B.; Zhang, Y.; Cao, Y. Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells. Proc. Natl. Acad. Sci. USA, 2010, 107, 15886-158891.
59. Lovren, F.; Pan, Y.; Quan, A.; Teoh, H.; Wang, G.; Shukla, P.C.; Levitt, K.S.; Oudit, G.Y.; Al-Omran, M.; Stewart, D.J.; Slutsky, A.S.; Peterson, M.D.; Backx, P.H.; Penninger, J.M.; Verma, S. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am. J. Physiol. Heart Circ. Physiol., 2008, 295, H1377-H1384.
60. Zhang, Y.-H.; Zhang, Y.H.; Dong, X.F.; Hao, Q.Q.; Zhou, X.M.; Yu, Q.T.; Li, S.Y.; Chen, X.; Tengbeh, A.F.; Dong, B.; Zhang, Y. ACE2 and Ang-(1-7) protect endothelial cell function and prevent early atherosclerosis by inhibiting inflammatory response. Inflamm. Res., 2015, 64, 253-260.
61. Dong, B.; Zhang, C.; Feng, J.B.; Zhao, Y.X.; Li, S.Y.; Yang, Y.P.; Dong, Q.L.; Deng, B.P.; Zhu, L.; Yu, Q.T.; Liu, C.X.; Liu, B.; Pan, C.M.; Song, H.D.; Zhang, M.X.; Zhang, Y. Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 1270-1276.
62. Epelman, S.; Tang, W.H.; Chen, S.Y.; Van Lente, F.; Francis, G.S.; Sen, S. Detection of soluble angiotensinconverting enzyme 2 in heart failure: Insights into the endogenous counter-regulatory pathway of the reninangiotensin-aldosterone system. J. Am. Coll. Cardiol., 2008, 52, 750-754.
63. Epelman, S.; Shrestha, K.; Troughton, R.W.; Francis, G.S.; Sen, S.; Klein, A.L.; Tang, W.H. Soluble angiotensinconverting enzyme 2 in human heart failure: Relation with myocardial function and clinical outcomes. J. Card. Fail., 2009, 15, 565-571.
64. Anguiano, L.; Riera, M.; Pascual, J.; Valdivielso, J.M.; Barrios, C.; Betriu, A.; Clotet, S.; Mojal, S.; Fernandez, E.; Soler, M.J.; investigators from the NEFRONA study. Circulating angiotensin converting enzyme 2 activity as a biomarker of silent atherosclerosis in patients with chronic kidney disease. Atherosclerosis, 2016, 253, 135-143.
65. Lely, A.T.; Hamming, I.; van Goor, H.; Navis, G.J. Renal ACE2 expression in human kidney disease. J. Pathol., 2004, 204, 587-593
66. Ye, M.; Wysocki, J.; William, J.; Soler, M.J.; Cokic, I.; Batlle, D. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensinconverting enzyme: Implications for albuminuria in diabetes. J. Am. Soc. Nephrol., 2006, 17, 3067-3075.
67. Soler, M.J.; Ye, M.; Wysocki, J.; William, J.; Lloveras, J.; Batlle, D. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. AJP Ren. Physiol., 2008, 296, F398-F405.
68. Ruiz-Ortega, M.; Ruperez, M.; Esteban, V.; Rodriguez-Vita, J.; Sanchez-Lopez, E.; Carvajal, G.; Egido, J. Angiotensin II: A key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol. Dial. Transplant, 2006, 21, 16-20.
69. Tikellis, C.; Johnston, C.I.; Forbes, J.M.; Burns, W.C.; Burrell, L.M.; Risvanis, J.; Cooper, M.E. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension, 2003, 41, 392-397.
70. Jessup, J.A.; Gallagher, P.E.; Averill, D.B.; Brosnihan, K.B; Tallant, E.A.; Chappell, M.C.; Ferrario, C.M. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am. J. Physiol. Heart Circ. Physiol., 2006, 291, H2166-H2172.
71. Soler, M.J.; Wysocki, J.; Batlle, D. ACE2 alterations in kidney disease. Nephrol. Dial. Transplant, 2013, 28, 2687-2697.
72. Ye, M.; Wysocki, J.; Naaz, P.; Salabat, M.R.; LaPointe, M.S.; Batlle, D. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: A renoprotective combination? Hypertension, 2004, 43, 1120-1125.
73. Mizuiri, S.; Hemmi, H.; Arita, M.; Ohashi, Y.; Tanaka, Y.; Miyagi, M.; Sakai, K.; Ishikawa, Y.; Shibuya, K.; Hase, H.; Aikawa, A. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am. J. Kidney Dis., 2008, 51, 613-623.
74. Reich, H.N.; Oudit, G.Y.; Penninger, J.M.; Scholey, J.W.; Herzenberg, A.M. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int., 2008, 74, 1610-1616.
75. Roberts, M.A.; Velkoska, E.; Ierino, F.L.; Burrell, L.M. Angiotensin-converting enzyme 2 activity in patients with chronic kidney disease. Nephrol. Dial. Transplant, 2013, 28, 2287-2294.
76. Tikellis, C.; Bialkowski, K.; Pete, J.; Sheehy, K.; Su, Q.; Johnston, C.; Cooper, M.E.; Thomas, M.C. ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes, 2008, 57, 1018-1025.
77. Velkoska, E.; Dean, R.G.; Burchill, L.; Levidiotis, V.; Burrell, L.M. Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition. Clin. Sci. (Lond)., 2008, 118, 269-279.
78. Velkoska, E.; Dean, R.G.; Griggs, K.; Burchill, L.; Burrell, L. M. Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. Clin. Sci. (Lond)., 2011, 120, 335-345.
79. Yamaleyeva, L.M.; Gilliam-Davis, S.; Almeida, I.; Brosnihan, K.B.; Lindsey, S.H.; Chappell, M.C. Differential regulation of circulating and renal ACE2 and ACE in hypertensive mRen2.Lewis rats with early-onset diabetes. Am. J. Physiol. Renal Physiol., 2012, 302, F1374-F1384.
80. Riera, M.; Anguiano, L.; Clotet, S.; Roca-Ho, H.; Rebull, M.; Pascual, J.; Soler, M.J. Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD mice beyond proteinuria. Am. J. Physiol. Renal Physiol., 2016, 310, F534-F546.
81. Burrell, L.M.; Gayed, D.; Griggs, K.; Patel, S.K.; Velkoska, E. Adverse cardiac effects of exogenous angiotensin 1-7 in rats with subtotal nephrectomy are prevented by ACE inhibition. PLoS One, 2017, 12, e0171975.
82. Clotet, S.; Riera, M.; Pascual, J.; Soler, M.J. RAS and sex differences in diabetic nephropathy. Am. J. Physiol. Ren. Physiol., 2016, 310, F945-F957.
83. Hallbauer, J.; Kreusch, S.; Klemm, A.; Wolf, G.; Rhode, H. Long-term serum proteomes are quite similar under highand low-flux hemodialysis treatment. Proteomics Clin. Appl., 2010, 4, 953-961.